Sentinel Lymph Node Biopsy for Gynecologic Cancers.

IF 4.7 4区医学 Q1 OBSTETRICS & GYNECOLOGY

Obstetrical & Gynecological Survey Pub Date : 2026-07-01 Epub Date: 2026-07-06 DOI:10.1097/OGX.0000000000001553

Romelyn Imperio-Onglao, Joseph Ng

{"title":"Sentinel Lymph Node Biopsy for Gynecologic Cancers.","authors":"Romelyn Imperio-Onglao, Joseph Ng","doi":"10.1097/OGX.0000000000001553","DOIUrl":null,"url":null,"abstract":"Importance: Determination of lymph node metastasis is crucial for prognosis and treatment strategies for gynecologic cancers. Assessing metastases using a sentinel lymph node biopsy (SLNBx) approach decreases surgical morbidity and improves quality of life.Objective: This review evaluates the efficacy, safety, and clinical utility of SLNB in gynecologic cancers to inform clinical practice and highlight areas for future research.Evidence acquisition: Endometrial, vulvar, cervical, and ovarian cancer studies on SLNB were obtained from databases including PubMed, Scopus, and Web of Science. The search focused on peer-reviewed articles, systematic reviews, meta-analyses, clinical practice guidelines, and expert consensus statements published in English.Results: SLNBx is an effective alternative to systematic lymphadenectomy for staging gynecologic malignancies. It is established for vulvar and endometrial cancer staging. For cervical cancer, the SENTICOL and SENTIX studies demonstrate high detection rates and comparable survival outcomes to lymphadenectomy with fewer comorbidities. In ovarian cancer, SLNBx detection rates vary, and additional research is needed to determine the role of SLNBx.Conclusions: Clinical studies support the use of SLNBx for staging of endometrial, vulvar, and cervical cancers. Future research and standardized protocols are essential to establish SLNBx as a standard practice in ovarian cancer.","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"81 7","pages":"345-354"},"PeriodicalIF":4.7000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/OGX.0000000000001553","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Importance: Determination of lymph node metastasis is crucial for prognosis and treatment strategies for gynecologic cancers. Assessing metastases using a sentinel lymph node biopsy (SLNBx) approach decreases surgical morbidity and improves quality of life.

Objective: This review evaluates the efficacy, safety, and clinical utility of SLNB in gynecologic cancers to inform clinical practice and highlight areas for future research.

Evidence acquisition: Endometrial, vulvar, cervical, and ovarian cancer studies on SLNB were obtained from databases including PubMed, Scopus, and Web of Science. The search focused on peer-reviewed articles, systematic reviews, meta-analyses, clinical practice guidelines, and expert consensus statements published in English.

Results: SLNBx is an effective alternative to systematic lymphadenectomy for staging gynecologic malignancies. It is established for vulvar and endometrial cancer staging. For cervical cancer, the SENTICOL and SENTIX studies demonstrate high detection rates and comparable survival outcomes to lymphadenectomy with fewer comorbidities. In ovarian cancer, SLNBx detection rates vary, and additional research is needed to determine the role of SLNBx.

Conclusions: Clinical studies support the use of SLNBx for staging of endometrial, vulvar, and cervical cancers. Future research and standardized protocols are essential to establish SLNBx as a standard practice in ovarian cancer.

查看原文本刊更多论文

妇科癌症前哨淋巴结活检。

重要性：确定淋巴结转移对妇科肿瘤的预后和治疗策略至关重要。使用前哨淋巴结活检（SLNBx）方法评估转移可降低手术发病率并提高生活质量。目的：评价SLNB在妇科肿瘤中的疗效、安全性和临床应用，为临床实践提供参考，并强调未来的研究领域。证据获取：子宫内膜癌、外阴癌、宫颈癌和卵巢癌的SLNB研究来自PubMed、Scopus和Web of Science等数据库。搜索的重点是同行评议的文章、系统评论、荟萃分析、临床实践指南和用英语发表的专家共识声明。结果：SLNBx是妇科恶性肿瘤分期的有效替代系统淋巴结切除术。它是为外阴和子宫内膜癌分期而建立的。对于子宫颈癌，SENTICOL和SENTIX研究显示出较高的检出率和与淋巴结切除术相当的生存结果，且合并症较少。在卵巢癌中，SLNBx的检出率各不相同，需要进一步的研究来确定SLNBx的作用。结论：临床研究支持使用SLNBx对子宫内膜癌、外阴癌和宫颈癌进行分期。未来的研究和标准化的方案对于建立SLNBx作为卵巢癌的标准做法至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obstetrical & Gynecological Survey 医学-妇产科学

CiteScore

2.70

自引率

3.20%

发文量

245

审稿时长

>12 weeks

期刊介绍： Each monthly issue of Obstetrical & Gynecological Survey presents summaries of the most timely and clinically relevant research being published worldwide. These concise, easy-to-read summaries provide expert insight into how to apply the latest research to patient care. The accompanying editorial commentary puts the studies into perspective and supplies authoritative guidance. The result is a valuable, time-saving resource for busy clinicians.